# Intalight

> Intalight is a US-based ophthalmic imaging company (the international brand of SVision Imaging / 视微影像, Luoyang, China) that builds high-speed swept-source OCT and OCT-angiography systems. Its flagship DREAM OCT platform images the whole eye in a single ultra-widefield scan, combining deep retinal penetration, anterior-segment imaging, biometry, and AI-driven segmentation for clinicians and researchers worldwide.

- **Founded:** 2014
- **Headquarters:** San Jose, California, United States
- **Founders:** Shawn Peng (Founder, Chairman & President), Bing Li (CEO & Co-Founder)
- **Team size:** ~22 (US-branded entity per third-party data; larger across the SVision Imaging operation in China)
- **Products:** DREAM OCT (VG200 / VG200D), Retina & Vitreous imaging, Anterior Segment imaging, AI segmentation & analysis
- **Notable:** Named to Medical Tech Outlook 'Top 10 Retinal Imaging Solutions Companies - 2023.', Received CE Mark for DREAM OCT in Europe (May 2025)., Approved by ANVISA in Brazil (June 2024) and NMPA-certified in China since 2019.

## Products & services

- **DREAM OCT (VG200 / VG200D)** — Flagship swept-source OCT/OCTA platform. DREAM = Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection, Multimodal imaging. ~200 kHz scan speed, ~1030-1070 nm tunable laser, up to 12 mm posterior imaging depth, and 130-degree ultra-widefield OCTA (about 26 mm x 21 mm) in a single scan.
- **Retina & Vitreous imaging** — Ultra-widefield retinal OCT and OCT-angiography with deep choroidal penetration, plus quantitative metrics such as vessel density, FAZ, choroidal vessel volume and choroidal vessel index.
- **Anterior Segment imaging** — AS-OCT and AS-OCTA with up to 16.2 mm scan depth in air, capturing cornea through anterior vitreous in a single scan, plus visualized biometry.
- **AI segmentation & analysis** — Automated deep-layer segmentation and OCT-angiography algorithms ('True-Angiography') that turn raw scans into quantitative clinical and research data.

## Achievements

- Named to Medical Tech Outlook 'Top 10 Retinal Imaging Solutions Companies - 2023.'
- Received CE Mark for DREAM OCT in Europe (May 2025).
- Approved by ANVISA in Brazil (June 2024) and NMPA-certified in China since 2019.
- Data from the platform cited in 170+ peer-reviewed publications.
- In a 2025 Scientific Reports study, DREAM (VG200D) completed widefield OCTA in ~9.1s vs ~23.3s for a comparator and showed strong deep-capillary-plexus visualization against Heidelberg, Topcon and Zeiss systems.

## Latest updates

- **2024-06** — DREAM OCT receives ANVISA regulatory approval in Brazil.
- **2025-05** — DREAM OCT receives CE Mark for the European market.
- **2025** — Scientific Reports publishes a comparison study placing DREAM OCTA against three established commercial systems.
- **2025-10** — Closed a Series D+ funding round; total funding reported at approximately $75M.

## Links

- Website: https://intalight.com
- LinkedIn: https://www.linkedin.com/company/intalight
- YouTube: https://www.youtube.com/channel/UCKi-jOjJ2rFrTldcMFqC3VA
- Facebook: https://www.facebook.com/profile.php?id=100084850507163

---

Profile page: https://yespress.io/intalight
Published by YesPress — https://yespress.io
Last updated: 2026-06-14